← Human Trials & Peer-Reviewed Studies
Immunomodulatory and clinical responses to zinc gluconate supplementation in patients with Behçet's disease: A double-blind, randomized placebo-controlled clinical trial.
Plain-language guide to PMID 35413570 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 50 patients.
Key Facts
- PMID
- 35413570
- Journal
- Clinical nutrition (Edinburgh, Scotland)
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Faghfouri AH et al. (10 authors)
- DOI
- 10.1016/j.clnu.2022.03.019
- Registered trial
- NCT05098678
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Toll-like receptor (TLR) 2 and 4 are involved in the pathogenesis of Behçet's disease (BD).
The current study aimed to investigate the effect of zinc supplementation on TLR-2/4 expression and the clinical manifestations of BD.
Who Took Part
According to the abstract, 50 patients were involved.
Before and after the intervention, the surface and mRNA expression level of TLR-2 and TLR-4 in the leukocytes, serum level of zinc and tumor necrosis factor-α (TNF-α), quality of life, anthropometric measures, and blood pressure of patients were collected.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
The effect sizes were compared between two groups using analysis of covariance.
What Was Measured
PubMed files the paper under topics including Behcet Syndrome, Dietary Supplements, Gluconates, Iran, Quality of Life, RNA, Messenger and Toll-Like Receptor 2.
The authors tagged it with the keywords Toll-like receptor 4, Tumor necrosis factor-alpha and Zinc.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 50 patients.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.